Trials of Trebananib, Amgen's ovarian cancer drug, prove disappointing

November 5, 2014 11:35 AM

13 0

Trials of Trebananib, Amgen's ovarian cancer drug, prove disappointing

The drug-maker Amgen Inc. has reported that the late-stage trial of an ovarian cancer drug called trebananib has failed to generate any significant results when it comes to improvement in patient's survival.

Located in the Conejo Valley, Amgen is the world's largest independent biotechnology firm. The company explained that the anti-tumor treatment drug was intended to be used alongside the chemotherapy drug paclitaxel so as to evaluate its efficacy and safety in a Phase 3 study.

Read more

To category page

Loading...